Loading…
← CockpitCompetitor Analysis › 603998.SS Hunan Fangsheng Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Hunan Fangsheng Pharmaceutical Co., Ltd. Class A603998.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum leader 88
Mkt cap
$719M
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$18.1M
20-day average traded
Fwd P/E
13.7×
forward earnings
ROIC−WACC
+11.2 pp
WACC 6.1%
Hurdle
-11 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥10.58
1D+0.4%
1W+4.7%
1M-0.8%
3M-1.8%
6M-1.1%
YTD-5.9%
1Y-10.3%
ATR %3.2%
52w lowhigh21.6% off high

What Hunan Fangsheng Pharmaceutical does

Employees: 1,868

Hunan Fangsheng Pharmaceutical at a glance

Size Hunan Fangsheng Pharmaceutical (603998.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $719M, the 2842nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.58 on 18 Nov 2026.

Performance Over six months the shares fell 1.1%, against -14.5% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 11.6% over the last twelve months (peer median -1.9%); the operating margin is 20.3% (peer median 9.6%).

Valuation It trades at 13.7× forward earnings against a peer median of 16.4× (4th cheapest of 9).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 11.2 points above its cost of capital (6.1% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026603998.SS 100Peer median 87
Six months, rebased to 100: Hunan Fangsheng Pharmaceutical against the median of its 20 peers (local-currency closes).

Hunan Fangsheng Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.88BCN¥1.73BCN¥1.76BCN¥1.61BCN¥1.78B
Revenue growth—-2%+9%-9%—
Gross profitCN¥1.43BCN¥1.19BCN¥1.21BCN¥1.04BCN¥1.13B
EBITDAn/aCN¥391MCN¥324MCN¥243MCN¥229M
Net incomeCN¥327MCN¥306MCN¥255MCN¥187MCN¥286M
Free cash flowCN¥544MCN¥342MCN¥100M-CN¥130MCN¥133M
Capital expenditureCN¥104MCN¥103MCN¥94.8MCN¥219MCN¥171M
Total debtCN¥230MCN¥471MCN¥764MCN¥829MCN¥659M

Quarterly statements and history in the cockpit →

Hunan Fangsheng Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%-10%0%+10%0570SGMT45346887996005306885662186600829300705NVCT600479498521710009150029070024246003513001LXRX688658603998.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Hunan Fangsheng Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%20×40×453468879968856621863007054985000915688658603998.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hunan Fangsheng Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%600530688566218660082930070560047949850029070024243001603998.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hunan Fangsheng Pharmaceutical is the large dot.

Hunan Fangsheng Pharmaceutical competitors and peer comparison

How Hunan Fangsheng Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hunan Fangsheng Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603998.SSPeer medianRank in peer set
1-month return-0.8%-7.1%7th highest of 21
6-month return-1.1%-14.5%6th highest of 21
Distance from 52-week high-21.6%-35.0%6th highest of 21
Revenue growth (TTM)+11.6%-1.9%3rd highest of 19
Operating margin20.3%9.6%3rd highest of 19
Forward P/E13.7×16.4×4th cheapest of 9
Growth the price implies (Req g, 7 yrs)-4.8%0.3%3rd least demanding of 12
Growth delivered (Del g)+6.4%0.0%3rd highest of 12
Hurdle (Req g minus delivered)-11.2 pp-1.4 pp3rd least demanding of 12
ROIC minus cost of capital+11.2 pp+0.5 pp2nd highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%13.7×-4.8%+6.4%
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%n/an/an/a
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%16.1×n/an/a
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%47.6×n/an/a
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%n/a42.7%-0.9%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%11.2×5.9%+11.3%
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%7.1×-11.8%+1.9%
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%n/a4.0%+5.3%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%16.7×-2.0%+26.1%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%n/a-2.1%0.0%
Earth 4985.TJapan$687M+7%+4%4%18.0×-1.6%-1.8%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%n/an/an/a
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%9.1×n/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%n/a9.4%-1.4%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%n/a13.5%-0.2%
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%n/a-8.3%-2.8%
Katakura Industries 3001.TJapan$765M+40%-2%15%n/a0.3%+0.5%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%n/an/an/a
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%24.9×n/an/a

Questions

Which companies are Hunan Fangsheng Pharmaceutical's closest peers?
The cockpit's peer set: China Traditional Chinese Medicine (0570.HK), Sagimet Biosciences (SGMT), Mochida Pharmaceutical (4534.T), Hunan Warrant Pharmaceutical (688799.SS), Shanghai Jiaoda Onlly (600530.SS), Jiangsu Jibeier Pharmaceutical (688566.SS), Luye Pharma (2186.HK), HPGC Renmintongtai Pharmaceutical (600829.SS).
Is Hunan Fangsheng Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 13.7× against a peer median of 16.4×, 4th cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has Hunan Fangsheng Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -1.1% against -14.5% for the median peer; over one year -10.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.